4.7 Review

Bacterial Translocation as Inflammatory Driver in Crohn's Disease

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2021.703310

Keywords

Crohn's disease; bacterial translocation; intestinal permeability; dysbiosis; NOD2; inflammatory response; anti-TNF-alpha

Funding

  1. FPU grant, Ministerio Innovacion, Ciencia y Universidad, Gobierno de Espana
  2. Asociacion Espanola para el Estudio del Higado
  3. Instituto ISABIAL, Hospital General Universitario de Alicante, Spain [UGP-2020-0287]
  4. Instituto de Salud Carlos III, Madrid, Spain [PI21/01702]

Ask authors/readers for more resources

This review explores the impact of bacterial antigen translocation, intestinal barrier permeability, host immune response, and genetic predisposition on the inflammatory response observed in CD patients. Evidence suggests that bacterial products translocating leads to uncontrolled inflammation in CD patients, with gut bacterial genomic fragments serving as a marker for increased risk of relapse.
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract responsible for intestinal lesions. The multifactorial etiology attributed to CD includes a combination of environmental and host susceptibility factors, which result in an impaired host-microbe gut interaction. Bacterial overgrowth and dysbiosis, increased intestinal barrier permeability, and altered inflammatory responses in patients with CD have been described in the past. Those events explain the pathogenesis of luminal translocation of bacteria or its products into the blood, a frequent event in CD, which, in turn, favors a sustained inflammatory response in these patients. In this review, we navigate through the interaction between bacterial antigen translocation, permeability of the intestinal barrier, immunologic response of the host, and genetic predisposition as a combined effect on the inflammatory response observed in CD. Several lines of evidence support that translocation of bacterial products leads to uncontrolled inflammation in CD patients, and as a matter of fact, the presence of gut bacterial genomic fragments at a systemic level constitutes a marker for increased risk of relapse among CD patients. Also, the significant percentage of CD patients who lose response to biologic therapies may be influenced by the translocation of bacterial products, which are well-known drivers of proinflammatory cytokine production by host immune cells. Further mechanistic studies evaluating cellular and humoral immune responses, gut microbiota alterations, and genetic predisposition will help clinicians to better control and personalize the management of CD patients in the future.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available